Question follow-through · 25099
Drugs: Gender
To ask the Secretary of State for Health and Social Care, what testing requirements are in place in the approval process to identify the different impacts of medicines on men and women.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 20 Jan 2025
- Target answer date
- 22 Jan 2025
- Answer
- 24 Jan 2025 · 4 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Mental Illness: Drugs · 21 Feb 2025
- Health Services: National Security · 23 Apr 2025
- Ritlecitinib: Alopecia · 19 May 2025
- Ritlecitinib: Alopecia · 19 May 2025
- Ritlecitinib: Alopecia · 19 May 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
20 Jan 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what testing requirements are in place in the approval process to identify the different impacts of medicines on men and women.
22 Jan 2025
Target answer date
Date supplied by the official written-questions record.
24 Jan 2025
Answer published
As part of the approval process for new drugs, the impact of sex, on men versus women, is assessed on pharmacokinetics, or exposure, pharmacodynamics, and overall efficacy and safety. The data is assessed in terms of whether any dose adjustments are warra...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Mental Illness: Drugs
21 Feb 2025 · To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Research has undertaken research on the potential impact of psychedelic medication on the treatment of severe mental health conditions.
Health Services: National Security
23 Apr 2025 · To ask the Secretary of State for Health and Social Care, if he will conduct an audit of health infrastructure classified as critically important to national interests to identify whether they contain Chinese-made components.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, what guidance his Department has issued to health boards on the prescription of Ritlecitinib to treat alopecia.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, on what age of patient health boards are advised to use Ritlecitinib to treat alopecia.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of Severity of Alopecia Tool scores to determine the correct treatment of alopecia.
Alopecia: Medical Treatments
19 May 2025 · To ask the Secretary of State for Health and Social Care, what discussions he has had with the British Association of Dermatologists on the suitability of Severity of Alopecia Tool scores to determine treatment for alopecia.
Alopecia: Medical Treatments
19 May 2025 · To ask the Secretary of State for Health and Social Care, what guidance his Department has issued to health boards on the factors that should be used to determine the severity of alopecia prior to a decision on treatment.
Alopecia: Medical Treatments
19 May 2025 · To ask the Secretary of State for Health and Social Care, whether Severity of Alopecia Tool scores are the only factor that health boards are advised to use when determining the correct treatment for alopecia.
Alopecia: Medical Treatments
19 May 2025 · To ask the Secretary of State for Health and Social Care, what factors health boards are advised to use in addition to Severity of Alopecia Tool scores when determining the correct treatment for alopecia.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, how many health boards have used Ritlecitinib to treat alopecia in the last 12 months.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, what guidance his Department provides to health boards on whether they should consider (a) the mental health impacts of alopecia and (b) other factors prior to prescribing Ritlecitinib.
Ritlecitinib: Alopecia
19 May 2025 · To ask the Secretary of State for Health and Social Care, whether he plans to update guidance on the use of Ritlecitinib to treat alopecia.